Patients characteristics at baseline
| n=442 (%) | |
| Male gender, n (%) | 223 (50.4) |
| Female gender, n (%) | 219 (49.6) |
| Age (years), mean (SD) | 36.2 (15) |
| Inflammatory bowel disease (IBD) | |
| Crohn disease, n (%) | 277 (62.7) |
| Ulcerative colitis, n (%) | 151 (34.8) |
| Indeterminate colitis, n (%) | 11 (2.5) |
| Disease duration (years), mean (SD) | 6.4 (8.2) |
| Previous inflammatory articular manifestations, n (%) | 74 (16.7) |
| Peripheral arthralgia associated with active IBD, n (%) | 27 (6.1) |
| Spondyloarthritis, n (%) | 37 (8.3) |
| Others, n (%) | 10 (2.3) |
| Psoriasis, n (%) | 9 (2) |
| Uveitis, n (%) | 4 (0.9) |
| Immunosuppressive therapy before or at the beginning of anti-TNFa | |
| Azathioprine, n (%) | 333 (75.3) |
| Methotrexate, n (%) | 51 (11.5) |
| Purinethol, n (%) | 45 (10.2) |
| Salazopyrine n (%) | 16 (3.6) |
| Cyclosporine, n (%) | 9 (2) |
| Others, n (%) | 17 (3.8) |
| First anti-TNFa received: | |
| Infliximab, n (%) | 283 (64) |
| Adalimumab, n (%) | 143 (32.4) |
| Golimumab, n (%) | 16 (3.6) |
| Associated treatment at first anti-TNFa initiation: | |
| Immunosuppressive therapy, n (%) | 265 (60) |
| Azathioprine, n (%) | 214 (48.4) |
| Purinethol, n (%) | 25 (5.7) |
| Methotrexate, n (%) | 24 (5.4) |
| Others, n (%) | 2 (0.5) |
| Corticosteroïds, n (%) | 170 (38.5) |
| Dose (mg), mean (SD) | 37.9 (19.4) |
TNF, tumour necrosis factor.